Discovery and subsequent therapeutic applications in immune checkpoints revolutionized the management of a broad range of malignancies, including non-small cell lung cancer (NSCLC). Several agents targeting PD-1/PDL1 and CTLA2 have become part of the routine practice in lung cancer management. Successful development of anti-PD-1/PDL1 axis includes their use in second-line, first-line, combination with chemotherapy, maintenance after definitive chemoradiation, adjuvant and neoadjuvant treatment with curative resection. Although we achieved regulatory approvals in these therapeutic settings, there remain numerous questions to be answered.
The goal of this special issue is to identify unsolved issues in immunotherapy that are unique and significant in NSCLC and to suggest hints to answer the questions.
We welcome submissions on the following topics but are not confined to:
● Single-agent and combination immunotherapy in metastatic NSCLC
● Neoadjuvant and adjuvant immunotherapy
● Maintenance immunotherapy after definitive local therapy
● Combination of immunotherapy and radiation
● Resistance mechanism in immunotherapy
● Role of immunotherapy in oncogene-driven NSCLC
● Management of immune-related toxicities in NSCLC